|Bid||3.9500 x 800|
|Ask||5.0800 x 1800|
|Day's Range||4.0000 - 4.2186|
|52 Week Range||2.6100 - 22.9900|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 4.35% and 2.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Aptinyx Inc (NASDAQ: APTX ) reported second-quarter results ahead of expectations and expressed confidence in its cash lasting into 2021. The company has an ongoing Phase 2 study and is progressing towards ...
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.77% and -2.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Every investor in Aptinyx Inc. (NASDAQ:APTX) should be aware of the most powerful shareholder groups. Institutions...
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of December 31st. In this article, we look at what those funds think of Aptinyx Inc. (NASDAQ:APTX) based on that data. […]
After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.
Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
Evanston, IL-based biopharma company Aptinyx Inc. is tanking Wednesday after the phase 2 trial for the company's diabetic peripheral neuropathy treatment did not meet its primary endpoint. The company said that the trial did not demonstrate statistically significant separation in outcomes when compared to a placebo in the double-blind controlled study of 300 patients suffering from the disease.